Takeda

NEWS DESK

Takeda Announces FY2023 Full Year Results and FY2024 Outlook

News Desk 2 09/05/2024

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant

NEWS DESK

Takeda Receives Positive CHMP Opinion for Fruquintinib

News Desk 2 26/04/2024

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC).

NEWS DESK

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education

News Desk 1 08/04/2024

Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two

NEWS DESK

Empathy in Action: Takeda’s Global Initiative Brings IBD Challenges

News Desk 1 19/03/2024

Takeda, the patient-centric biopharmaceutical company, brought its global ‘In Their Shoes’ program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients. It is estimated that

NEWS DESK

Takeda Brings Renewed Hope to People Living with Inflammatory Bowel Disease in Oman

News Desk 1 11/03/2024

Global biopharmaceutical company Takeda hosted a medical conference today in Muscat, Oman, in which leading IBD medical experts from across the Gulf Cooperation Council (GCC) convened to discuss the latest innovations and medical research in IBD treatment. Globally, there are 10 million Ulcerative colitis and Crohn’s disease patients, with that number increasing year